Stock code: 603233 Securities abbreviation: Dasanlin
The Board of Directors and all Directors of the Company warrant that the contents of this announcement are free from any misrepresentation, misleading statement or material omission and accept sole and several liability for the truthfulness, accuracy and completeness of the contents.
Important Content Tips:
The board of directors, the board of supervisors and the directors, supervisors and senior management of the company guarantee that the contents of the quarterly report are true, accurate and complete, that there are no false records, misleading statements or material omissions, and that they bear individual and joint legal liabilities.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting institution (accounting supervisor) ensure that the financial statement information in the quarterly report is true, accurate and complete.
Whether the third quarter financial statements were audited
□ Yes √ No
First, the main financial data
(i) Key accounting data and financial indicators
Unit: Yuan Currency: RMB
Note: "Reporting Period" refers to the 3-month period from the beginning of the quarter to the end of the quarter, the same below.
(ii) Non-recurring profit or loss items and amounts
The non-recurring profit and loss items listed in the Interpretive Announcement on the Disclosure of Information of Companies Publicly Offering Securities No. 1 - Non-recurring Profit and Loss are defined as recurring profit and loss items
□ apply √ does not apply
(3) Changes in major accounting data and financial indicators, and reasons
√ applicable □ does not apply
II. Shareholder Information
(1) A table of the total number of common shareholders and the number of preferred shareholders whose voting rights have been restored and the shareholdings of the top ten shareholders
Unit: Shares
3. Other reminders
Other important information about the Company's operations during the reporting period that investors need to be reminded of
During the reporting period, the company mainly had 29 investment and mergers and acquisitions in the same industry, of which 9 M&A projects in the previous year were completed in the current year, and 20 were newly signed M&A projects; the number of stores involved was 839 (of which 428 were signed and undelivered stores); the details are as follows:
(1) In September 2019, the Company signed a "Cooperation Agreement" with Wang Liqun and Wang Qin, agreeing that Wang Liqun and Wang Qin would fund the establishment of a pharmaceutical chain company (hereinafter referred to as the new company) and inject the assets and business integration of the five stores under their name into the new company. After the injection of business and assets, the company acquired the equity of the new company. The integration was completed in February 2021, and the company signed a "capital increase and share expansion agreement" with the new company (Heilongjiang Lingzhifeng Pharmacy Chain Co., Ltd.) to obtain 51% of the new company for 94.61 million yuan, and the project was completed in March 2021, with 13 stores at the time of delivery.
(2) In July 2020, the subsidiary Xinyang Baiminfu Pharmaceutical Chain Co., Ltd. signed a "Cooperation Agreement" with Li Wenping and Zhang Weiguo, agreeing that Li Wenping and Zhang Weiguo would form a new company and inject the assets and business integration of 10 stores under their name, huaibin County Kangmintang Pharmaceutical Retail Chain Co., Ltd., into the new company, and Xinyang Baiminfu Company would acquire 51% of the equity of the new company for 13.4225 million yuan, and the project would be completed in April 2021.
(3) In November 2020, the subsidiary Nantong JianghaiDa Pharmacy Chain Co., Ltd. signed the "Asset Acquisition Contract" with Jianhu County Times Pharmacy Co., Ltd., Jianhu County Times Shengshi Pharmacy Co., Ltd., Jianhu County Times Jianning Pharmacy Co., Ltd., Jianhu County Times Wenhui Pharmacy Co., Ltd., Jianhu County Times Civilian Pharmacy Co., Ltd., Jianhu County Times Aixin Pharmacy Co., Ltd., and Jianhu County Times Construction Pharmacy Co., Ltd., agreeing to 1, 5 million yuan to acquire the assets and business related to the above 7 stores, the asset acquisition project was completed in January 2021.
(4) In November 2020, the Company and its subsidiary Jixi Dashanlin Lingfeng Pharmacy Chain Co., Ltd. signed the "Capital Increase and Share Expansion Agreement" with Luan Bin and Tan Dongwei, agreeing to increase the capital of Mudanjiang Tianli Pharmaceutical Chain Co., Ltd. held by them by 25.85 million yuan and obtain 19% of the equity of the company. In August 2021, the Company and its subsidiary Jixi Dashanlin Lingfeng Pharmacy Chain Co., Ltd. signed an Equity Transfer Agreement with Luan Bin, agreeing to acquire 42% of the equity of Mudanjiang Tianli Pharmaceutical Chain Co., Ltd. for RMB42.96 million, holding a total of 61% of the equity, involving 21 stores, and the project was completed in September 2021.
(5) In December 2020, its subsidiary, Jixi Dashanlin Lingfeng Pharmacy Chain Co., Ltd., signed an Equity Transfer Agreement with Sun Wei and Zhang Hui, agreeing to acquire 100% of the equity of Jixi Changshoutang Innovative Pharmacy Chain Co., Ltd., which it owns for RMB38.29 million, involving 17 stores, and the project was completed in February 2021.
(6) In December 2020, its subsidiary, Nantong JianghaiDa Pharmacy Chain Co., Ltd., and Leping Zhanshun Enterprise Management Center (Limited Partnership) signed the Equity Transfer Agreement, agreeing to acquire its 65% equity interest in Taizhou GuotaiDa Pharmacy Chain Co., Ltd. for RMB42.96 million, involving 39 stores, and the project was completed in March 2021.
(7) In December 2020, the Company and its subsidiary Baoding Yimin Pharmaceutical Retail Chain Co., Ltd. signed an Equity Transfer Agreement with Leping Tianrui Enterprise Management Center (Limited Partnership), agreeing to acquire its 56% equity interest in Hebei Yiyou Pharmaceutical Chain Co., Ltd. for RMB23.308 million, involving 26 stores, and the project was completed in July 2021.
(8) In December 2020, the Company and its subsidiary Baoding Yimin Pharmaceutical Retail Chain Co., Ltd. signed the Equity Transfer Agreement with Leping Lihong Enterprise Management Center (Limited Partnership), agreeing to acquire 56% of the equity of Baoding Xukang Pharmaceutical Co., Ltd. held by it for 7.11 million yuan, involving 15 stores, and the project was completed in June 2021.
(9) In December 2020, the subsidiary Nantong JianghaiDa Pharmacy Chain Co., Ltd. signed a "Cooperation Agreement" with Shi Huaying, Xue Jie, Sheng Guoying, Ju Xiaoxia, Xu Jiangang, and Changzhou Jian'anDa Pharmacy Co., Ltd., agreeing to fund the establishment of a pharmaceutical chain company (hereinafter referred to as the new company). In July 2021, its subsidiary, Nantong Jianghai Pharmacy Chain Co., Ltd., and Leping Xingke Enterprise Management Center (Limited Partnership) signed an Equity Transfer Agreement, agreeing to acquire 65% of its equity in the new company for 19.73 million yuan, involving 19 stores, and the project was completed in August 2021.
(10) In January 2021, the Company signed the Equity Transfer Agreement with Chongqing Wanjiayan Hospital Co., Ltd., whereby the Company acquired its 19% equity interest in Chongqing WanjiayanDa Pharmacy Co., Ltd. for RMB34.08 million. In September 2021, the Company signed an Equity Transfer Agreement with Chongqing Wanjiayan Hospital Co., Ltd. to acquire its 32% equity interest in Chongqing Wanjiayan Pharmacy Co., Ltd. for RMB57.616 million, with a total of 51% equity, involving 129 stores, and the project is underway.
(11) In January 2021, the subsidiary Nantong JianghaiDa Pharmacy Chain Co., Ltd. signed an Asset Acquisition Contract with Tongjida Pharmacy Chain Co., Ltd. in Chongchuan District, Nantong City, agreeing to acquire the relevant assets and businesses of 11 stores of Tongjida Pharmacy Chain Co., Ltd. in Chongchuan District, Nantong City for 7.8 million yuan, and the project was completed in April 2021.
(12) In February 2021, the subsidiary Henan Dashanlin Pharmacy Chain Co., Ltd. signed the Equity Acquisition Contract with Pan Xuehua and Wang Zhijun, agreeing to acquire 51% of the equity held by Henan Yanhuangda Pharmacy Chain Co., Ltd. for 68.34416 million yuan, involving 59 stores, and the project was completed in April 2021.
(13) In February 2021, the Company signed the Equity Transfer Agreement with Qingshen Xingchen Business Service Partnership (General Partnership), agreeing to acquire its 51% equity interest in Deyang Dacheng Family Health Chain Pharmacy Co., Ltd. for RMB31.53 million, involving 49 stores, and the project is underway.
(14) In February 2021, the Company signed an Equity Transfer Agreement with Leping Kangda Enterprise Management Center (Limited Partnership), agreeing to acquire its 51% equity interest in Huishan Runkang Plaza Pharmaceutical Chain Co., Ltd. for RMB37.31 million, involving 33 stores, and the project was completed in September 2021.
(15) In February 2021, the Company and its subsidiary Heilongjiang Lingzhifeng Pharmacy Chain Co., Ltd. signed an Equity Transfer Agreement with Shao Wanyi and Shao Nan to acquire 56% of the equity of Qiqihar Xinte Pharmaceutical Chain Co., Ltd. held by them for RMB23.22 million, involving 18 stores, and the project was completed in June 2021.
(16) In March 2021, the Company and its subsidiary Xi'an Xinkangda Pharmacy Chain Co., Ltd. signed an Equity Transfer Agreement with Chen Jianlin and Yao Aiqin, agreeing to acquire 56% of the equity of Xi'an Wanbaiquan Pharmaceutical Co., Ltd. for 46.9 million, involving 55 stores, and the project is underway.
(17) In March 2021, the Company signed an Equity Transfer Agreement with Zhao Li and Wang Xiaojun to acquire its 19% equity interest in Chengdu Yifeng Likang Pharmaceutical Chain Co., Ltd. for RMB15.37 million. In June 2021, the Company signed the Equity Transfer Agreement with Heze Haikong Enterprise Management Cooperative Enterprise (Limited Partnership) to acquire its 32% equity interest in Chengdu Yifeng Likang Pharmaceutical Chain Co., Ltd. for RMB30.72 million, holding a total of 51% of the equity, involving 12 stores, and the project was completed in August 2021.
(18) In April 2021, the subsidiary Nantong JianghaiDa Pharmacy Chain Co., Ltd. signed the "Capital Increase and Share Expansion Agreement" with Sun Yong, agreeing to increase the capital of Yangzhou People's Home Pharmaceutical Chain Co., Ltd. for 12.71 million yuan and obtain 51% of the equity, involving 14 stores, and the project was completed in August 2021.
(19) In June 2021, the subsidiary Meizhou Dashanlin Pharmacy Co., Ltd. signed an Asset Acquisition Contract with Meizhou YiminDa Pharmacy Chain Co., Ltd. to acquire the tangible assets and intangible assets of 20 stores of Meizhou YiminDa Pharmacy Chain Co., Ltd. for 15 million yuan, and the project was completed in September 2021.
(20) In June 2021, the Company and its subsidiary Heilongjiang Lingzhifeng Pharmacy Chain Co., Ltd. signed an Equity Transfer Agreement with Daqing Pharmaceutical Co., Ltd. to acquire its 56% equity interest in Daqing Foster Pharmaceutical Chain Co., Ltd. for RMB26.47 million, involving 18 stores, and the project was completed in August 2021.
(21) In June 2021, the Company signed the Equity Transfer Agreement with Wang Yingjie, Yuan Jun and Rong Haiyan to acquire 100% of the equity of Hebei Yibao Pharmaceutical Technology Co., Ltd. held by the company for 10 million yuan, and the target company has drug wholesale qualifications, and the project is underway.
(22) In July 2021, its subsidiary, Maoming Dashanlin Chain Pharmacy Co., Ltd., signed an Asset Acquisition Contract with Guangdong Wanshoutang Pharmaceutical Chain Co., Ltd. to acquire the tangible and intangible assets of 35 stores of Guangdong Wanshoutang Pharmaceutical Chain Co., Ltd. for RMB32.53 million, and the project was completed in September 2021.
(23) In July 2021, the subsidiary Nantong JianghaiDa Pharmacy Chain Co., Ltd. signed the "Capital Increase and Share Expansion Agreement" with Zhang Ping, agreeing to increase the capital of Nanjing Baijia Kangda Pharmacy Co., Ltd. for 8.3265 million yuan and obtain 51% of the equity, involving 10 stores, and the project is underway.
(24) In August 2021, its subsidiary, Maoming Dashenlin Chain Pharmacy Co., Ltd., signed an Asset Acquisition Contract with Guangdong Huizetang Xinli Pharmaceutical Chain Co., Ltd., Maoming Huizetang Pharmaceutical Co., Ltd., Gaozhou Huizetang Pharmaceutical Co., Ltd., and Gaozhou Chengxi Huizetang Pharmaceutical Co., Ltd., acquiring the tangible and intangible assets of 12 stores held by Guangdong Huizetang Xinli Pharmaceutical Chain Co., Ltd., Maoming Huizetang Pharmaceutical Co., Ltd., Gaozhou Huizetang Pharmacy, and Gaozhou Chengxi Huizetang Pharmacy for RMB7.2 million. The project was completed in September 2021.
(25) In August 2021, its subsidiary, Ganzhou Dashanlin Chain Pharmacy Co., Ltd., signed an Asset Acquisition Contract with Renji Pharmacy in Ningdu County to acquire the tangible and intangible assets of 11 stores of Renji Pharmacy in Ningdu County for RMB10.1 million, and the project is underway.
(26) In August 2021, its subsidiary, Jixi Dashanlin Lingfeng Pharmacy Chain Co., Ltd., signed an Equity Transfer Agreement with Mudanjiang Tianli Pharmaceutical Chain Co., Ltd. to acquire 100% of the equity of Qitaihe Tianli Pharmaceutical Chain Co., Ltd., involving 12 stores, and the project was completed in September 2021.
(27) In September 2021, henan dashanlin chain pharmacy co., ltd., a subsidiary, signed a "cooperation agreement" with Lin Baige, Lin Baimin, Lin Qingwa, Chen Huizhen and Li Shengli, agreeing that Lin Baige and five other people would fund the establishment of a pharmaceutical chain company (hereinafter referred to as the new company) and inject the assets and business integration of 48 stores under its name into the new company. After the injection of business and assets, subsidiary Henan Dashanlin acquired a 51% stake in the new company for RMB29.87 million, and the project is underway.
(28) In July 2021, the Company signed a "Cooperation Agreement" with Pan Peng, Zeng Hun and Pan Yuesheng, agreeing to invest in the establishment of Hubei Jiakang Junan Pharmaceutical Chain Co., Ltd. (hereinafter referred to as the new company) and integrate assets and business. In September 2021, the Company signed the Equity Transfer Agreement with Hebi Ruikang Enterprise Management Consulting Partnership (Limited Partnership), agreeing to acquire 32.36% of the equity of the new company held by it for 17.36 million yuan, and after meeting the conditions, the company will increase its capital by 20.40816 million yuan to obtain 18.64% of the equity, holding a total of 51% of the equity, involving 41 stores, and the project is underway.
(29) In September 2021, the Company and its subsidiary Heilongjiang Lingzhifeng Pharmacy Chain Co., Ltd. signed a "Cooperation Agreement" with 13 original shareholders, including Bai Yuming, Huang Shiyu and Yao Xiuying, agreeing to acquire 70% of the equity of Heilongjiang Taihua Pharmaceutical Chain Sales Co., Ltd. for 125.85 million yuan, involving 85 stores, and the project is underway.
4. Quarterly financial statements
(i) Type of audit opinion
(ii) Financial statements
Consolidated balance sheets
September 30, 2021
Compilation unit: Dashenlin Pharmaceutical Group Co., Ltd
Unit: Yuan Currency: RMB Audit Type: Unaudited
Person in charge of the company: Ke Yunfeng Person in charge of accounting work: Peng Guangzhi Head of accounting institutions: Chen Weifeng
Consolidated income statement
January-September 2021
Compilation unit: Dashenlin Pharmaceutical Group Co., Ltd
In the event of a merger of enterprises under the same control in the current period, the net profit realized by the merged party before the merger is: 0 yuan, and the net profit realized by the merged party in the previous period is: 0 yuan.
Consolidated cash flow statement
Unit: Yuan Currency: RMB Audit Type: Unaudited
(3) The first implementation of the new lease standard from 2021 onwards to adjust the relevant circumstances of the financial statements at the beginning of the first implementation year
Unit: Yuan Currency: RMB
Explanation of the adjustment of each project:
Effective January 1, 2021, the Company implemented the revised Accounting Standard for Business Enterprises No. 21 - Leases by the Ministry of Finance. In accordance with the relevant provisions on the interface between the old and new standards, the information for the comparable period will not be adjusted, and the cumulative impact of the implementation of the new standard on the first implementation date will be retroactively adjusted for the amount of retained earnings and other related items in the financial statements at the beginning of the reporting period.
This is hereby announced.
Dashenlin Pharmaceutical Group Co., Ltd
board of directors
October 28, 2021
Stock code: 603233 Stock abbreviation: Dasanlin Announcement number: 2021-079
Announcement on the departure of senior management
Dashenlin Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") recently received a written resignation report from Mr. Ke Jinlong, Deputy General Manager of the Company. Mr. Ke Jinlong applied to resign as deputy general manager of the Company due to personal reasons, and Mr. Ke Jinlong remained a director of the Company after his resignation.
As at the date of this announcement, Mr. Ke Jinlong holds 159,466,562 shares of the Company with unlimited sale conditions, representing 20.18% of the total share capital of the Company. In the future, it will continue to strictly abide by the relevant provisions of laws and regulations, manage the shares it holds, and strictly fulfill its commitments.
In accordance with the relevant regulations, the resignation report of Mr. Ke Jinlong shall take effect from the date of delivery to the Board of Directors of the Company. Mr. Ke Jinlong has been diligent and conscientious during his term of office, and the Board of Directors of the Company expresses its heartfelt thanks to Mr. Ke Jinlong for his contribution to the development of the Company!